Clinical Trial: A Prospective, Single-Arm Clinical Study of Transarterial Chemoembolization (TACE) Followed by Ablation in Combination with Camrelizumab and Apatinib for the Treatment of Giant Hepatocellular Carcinoma (China)

China, Oct. 5 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Prospective, Single-Arm Clinical Study of Transarterial Chemoembolization (TACE) Followed by Ablation in Combination with Camrelizumab and Apatinib for the Treatment of Giant Hepatocellular Carcinoma'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600133729

Registration Time: 2026/10/03

Type: Interventional study

Primary Sponsor: Peking University First Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=317430

Published by HT Digital Content Services with permission from Health Daily Digest....